Earnings Ahead

VRTX - Vertex Pharmaceuticals Incorporated

385.76 9.56 2.54

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

About

Profile

Vertex Pharmaceuticals Incorporated discovers, develops, and commercializes pharmaceutical products. The Company develops drugs for the treatment of cystic fibrosis, cancer, inflammatory bowel, autoimmune disease, and neurological disorders. Vertex Pharma


Headquarters

Boston, Massachusetts, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

VRTX



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Vertex shares dip 2% as Q3 revenue, guidance falls shy of Street estimates
  • Vertex Pharmaceuticals Non-GAAP EPS of $4.08 beats by $0.11, revenue of $2.48B misses by $20M
  • Earnings week ahead: Disney, AMC, Plug Power, Lucid, Realty Income and more
  • Biotechs rally with gene editing stocks among notable gainers
  • Vertex Pharmaceuticals Q3 2023 Earnings Preview
  • Goldman Sachs' 25 'conviction list' stocks to buy
  • Biggest stock movers today: AMD, WeWork, Paycom Software, CRISPR Therapeutics and more
  • CRISPR gains after FDA AdCom on gene editing therapy
  • CRISPR, Vertex gene editing therapy gets warm response from FDA panel
  • Gene editing stocks gain after Eli Lilly deal amid FDA AdCom
  • CRISPR on hold for trading amid key FDA meeting on gene editing drug
  • Pharma, PBMs spar over rising drug costs amid public scrutiny
  • FDA reviewers recommend more studies for Vertex sickle cell therapy: report
  • Editas upgraded at Citi ahead of FDA AdCom on gene editing therapy
  • Vertex Pharmaceuticals marketing chief disposes $2M worth stock
  • Vertex Pharmaceuticals executive chairman disposes stake worth $4.85M
  • Vertex updated data on diabetes candidate VX-880 encouraging
  • Vertex appoints Atkinson EVP Chief Technical Operations Officer
  • Bluebird bio favored at Baird as sickle cell disease space gets busy
  • Lilly's market cap soared 36% in Q2, eclipsing J&J, Merck, Novo Nordisk
PEERS
/XLV

XLV

Earnings History

Date EPS / Forecast Revenue / Forecast
January 26, 2022 3.37 / 3.29 2.07B / 2B Beat!
November 2, 2021 3.56 / 3.09 1.98B / 1.86B Beat!
July 29, 2021 3.11 / 2.53 1.79B / 1.72B Beat!
April 29, 2021 2.98 / 2.7 1.72B / 1.66B Beat!
February 1, 2021 2.51 / 2.57 1.63B / 1.59B Beat!
October 29, 2020 2.64 / 2.35 1.54B / 1.49B Beat!
July 30, 2020 2.61 / 2.09 1.52B / 1.39B Beat!
April 29, 2020 2.56 / 1.87 1.52B / 1.3B Beat!
January 30, 2020 1.7 / 1.21 1.26B / 1.01B Beat!
October 30, 2019 1.23 / 1.15 949.83M / 950.95M
July 31, 2019 1.26 / 1.07 941.28M / 886.16M Beat!
April 30, 2019 1.14 / 1.01 858.29M / 851.35M Beat!
February 5, 2019 1.3 / 1.06 869.44M / 820.13M Beat!
October 24, 2018 1.09 / 1.02 783.86M / 790.69M
July 25, 2018 0.94 / 0.75 751.22M / 680.64M Beat!
April 26, 2018 0.76 / 0.63 638.88M / 622.11M Beat!
January 31, 2018 0.61 / 0.53 651.6M / 595.92M Beat!
October 25, 2017 0.53 / 0.31 578.2M / 520.1M Beat!
July 26, 2017 0.39 / 0.35 1.26B / 487.5M Beat!
April 27, 2017 0.41 / 0.37 714.7M / - Beat!
Date Price Open High Low Vol Change
Nov 20 451.23 448.46
451.76
445.38
1.5M 0.72%
Nov 19 448.01 462.8
463.9
447.14
2.2M -4.07%
Nov 18 467.01 465.19
468.88
458.05
1.1M 0.28%
Nov 15 465.7 478.56
479.93
458.1
2.6M -3.77%
Nov 14 483.96 495.62
496.33
483.55
1.2M -2.15%
 
Nov 13 494.61 491.34
498.25
491.03
1.1M 0.94%
Nov 12 490 503
508.04
489.02
1.4M -2.34%
Nov 11 501.72 518.27
518.35
500.13
1.3M -2.91%
Nov 8 516.74 507.17
519.88
504.94
1.3M 2.84%
Nov 7 502.45 493.7
504.31
486.64
992K 1.78%
Nov 6 493.64 505.35
506.65
485.29
1.6M -1.25%
Nov 5 499.88 483
503.2
474
1.7M 5.73%
Nov 4 472.8 473.91
475.48
468.77
1.2M 0.36%
Nov 1 471.12 471.06
475.73
463.14
1.4M -1.02%
Oct 31 475.98 471.58
477.7
468.98
1.4M 0.19%
Oct 30 475.08 470.44
475.46
468.47
722K 1%
Oct 29 470.36 476.33
478.06
469.62
1,000K -1.26%
Oct 28 476.37 477.95
478.32
474.68
501K -0.28%
Oct 25 477.7 477.2
480.41
475.05
1.0M 1.23%
Oct 24 471.91 473.35
477.84
471.87
674K 0.40%
Oct 23 470.05 474.47
477.47
464.78
991K -1.02%
Oct 22 474.91 479.43
482.87
473.58
1.1M -0.67%
Oct 21 478.09 480.17
487.88
477.66
690K -1.02%
Oct 18 483 498.3
498.63
480.79
2.3M -3.15%
Oct 17 498.73 490
499.09
487.96
1.0M 2.36%
Oct 16 487.25 480.82
488.48
480.7
725K 0.61%
Oct 15 484.3 487.01
488
480.79
1.3M -0.11%
Oct 14 484.82 481.64
487.09
478.9
744K 0.65%
Oct 11 481.71 478.53
482.89
475.87
940K 1.17%
Oct 10 476.15 467.49
477
464.85
1.1M 1.75%
Oct 9 467.97 460
468.16
456.16
1.0M 1.97%
Oct 8 458.94 452.03
459.87
451.11
1.3M 2.30%
Oct 7 448.6 454.17
454.36
447.7
914K -1.47%
Oct 4 455.31 454.98
458.14
452.62
782K 0.39%
Oct 3 453.55 460
462.13
452.26
993K -1.86%
Oct 2 462.14 462.6
468.07
460.55
897K -1.62%
Oct 1 469.76 472
472.31
461.36
1.1M 1.01%
Sep 30 465.08 463.16
467.57
461.41
808K 0.48%
Sep 27 462.88 466.01
467.57
461.49
711K -0.06%
Sep 26 463.15 462.08
465.32
458.1
948K 0.30%
Sep 25 461.76 463.09
464.88
458.54
778K -0.27%
Sep 24 462.99 459.59
466.08
456.07
1.4M 0.65%
Sep 23 460 464.92
465.75
458.55
975K -1.06%
Sep 20 464.92 474.36
474.93
463.81
2.2M -2.72%
Sep 19 477.9 477.7
483.98
476.27
940K 0.79%
Sep 18 474.16 483.78
483.78
473.75
868K -1.48%
Sep 17 481.26 486.42
487.23
477.17
1.3M -1.67%
Sep 16 489.43 490
490.15
483.95
696K 0.84%
Sep 13 485.37 480
486.06
478.75
701K 1.40%
Sep 12 478.65 474.74
479.51
468.46
738K 0.82%
Sep 11 474.74 469.07
476.11
460.69
948K 0.84%
Sep 10 470.78 471.53
473.11
466.03
720K -0.07%
Sep 9 471.11 472.23
473.68
468.96
776K 0.66%
Sep 6 468 467.92
471.89
463.04
1.1M -0.12%
Sep 5 468.57 477.73
477.73
463.41
833K -2.09%
Sep 4 478.57 476.82
480.14
472.83
872K 0.60%
Sep 3 475.7 492.65
493
474.58
1.8M -4.07%
Aug 30 495.89 495.67
500.25
492.29
1.8M 0.51%
Aug 29 493.35 491.19
497.5
487.93
707K 0.74%
Aug 28 489.73 481.89
493.94
480.05
942K 0%